Table 3.

Total meta-analysis outcomes and stratified analysis of each endpoint based on study design and duration of follow-up

Endpoints	Subgroup	Study, n	RR	95% CI	Pvalue	I2 (%)	Pheterogeneity
All-cause death	Total	15	1.23	1.00–1.52	0.05	77	< 0.001
	RCT	6	1.30	0.86–1.98	0.08	70	0.005
	OS	9	1.22	0.95–1.56	0.12	81	< 0.001
	Mid-term	7	1.12	0.76–1.65	0.58	61	0.02
	Long-term	8	1.32	1.04–1.67	0.02	82	< 0.001
MACCE	Total	8	1.59	1.38–1.85	< 0.001	68	0.003
	RCT	5	1.40	1.20–1.63	< 0.001	26	0.25
	OS	3	1.87	1.72–2.03	< 0.001	0	0.52
	Mid-term	3	1.31	1.11–1.54	0.001	14	0.31
	Long-term	5	1.84	1.70–1.99	< 0.001	0	0.58
Cardiac death	Total	7	1.76	1.11–2.80	0.02	71	0.002
	RCT	4	2.25	1.28–3.98	0.005	65	0.04
	OS	3	1.20	0.92–1.56	0.18	0	0.93
	Mid-term	4	1.99	0.96–4.15	0.07	70	0.02
	Long-term	3	1.37	0.99–1.90	0.06	18	0.30
MI	Total	11	1.98	1.53–2.57	< 0.001	64	0.002
	RCT	5	1.35	0.97–1.86	0.07	42	0.14
	OS	6	2.44	2.07–2.88	< 0.001	3	0.40
	Mid-term	5	1.53	0.95–2.48	0.08	69	0.01
	Long-term	6	2.35	2.01–2.73	< 0.001	0	0.61
Stroke	Total	12	0.71	0.48–1.03	0.07	66	< 0.001
	RCT	6	0.44	0.27–0.71	< 0.001	0	0.76
	OS	6	0.95	0.62–1.45	0.81	72	0.003
	Mid-term	6	0.39	0.23–0.66	< 0.001	0	0.86
	Long-term	6	0.95	0.64–1.41	0.79	72	0.004
Repeat revascularization	Total	12	2.61	2.08–3.29	< 0.001	79	< 0.001
	RCT	5	2.22	1.46–3.39	< 0.001	78	0.001
	OS	7	2.92	2.21–3.87	< 0.001	79	< 0.001
	Mid-term	6	2.88	1.66–4.99	< 0.001	84	< 0.001
	Long-term	6	2.56	2.02–3.24	< 0.001	75	0.001

Italic values indicate significance of P value (P_value and P_{heterogeneity} < 0.05)

RR risk ratio, CI confidence intervals, MACCE major adverse cardiac and cerebrovascular event, MI myocardial infarction, RCT randomized controlled trials, OS observational studies, Mid-term 1–3 years follow-up, Long-term > 3 years follow-up